IO Biotech, Inc. (id:8414 IOBT)

0.682 USD

Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/21/2024 8:23:59 PM)

Exchange closed, opens in 13 hours 5 minutes

• 1 day
• 1 week
• 1 month
• 6 months
• 1 year
• All

About IO Biotech, Inc.

Market Capitalization 63.91M

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.